Gujarat: Over 750 volunteers get Covaxin first dose in phase-3 trial

Over 750 volunteers have been

administered the first dose of Bharat Biotech’s COVID-19 vaccine ‘Covaxin’ as part of its phase-3 trials at a city hospital, and none of them have experienced any side effects so far, a senior doctor said on Sunday.

is developing Covaxin in collaboration with the Indian Council of Medical Research (ICMR)-National Institute of Virology (NIV).

The phase-III trials of the vaccine are being conducted at Sola Civil Hospital here.

“Over 750 volunteers, including around 50 health workers like doctors, nursing staff, para-medics, have been administered the first dose of Covaxinsince its phase-3 trial began on November 25. None of the volunteers have experienced any kind of side effects so far,” Dr Kiran Rami, head of the hospital’s TB and chest department, told PTI.

“A total 1,000 volunteers will be administered the vaccine by the end of this month. We have also begun giving the second booster dose to the volunteers who have completed 28 days of the first dose. We have covered 15 volunteers so far,” he said.

For the second booster dose, those who completed 28 days, are being called by the hospital. The volunteers were also given a diary with the details of their schedule, Dr Rami said.

The first dose of the vaccine is given after the mandatory RT-PCR test. However, for the second booster dose, no such test is required when the vaccine is administered. But the volunteers will have to undergo RT-PCR test every month for ten months, he said.

Sola civil hospital at Ahmedabad in Gujarat has been chosen for the phase-3 human trials of Covaxin on 1,000 volunteers.

had earlier received approval for the phase-3 clinical trials on 26,000 participants in over 25 centres across India.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Source link

Leave a Comment

Your email address will not be published. Required fields are marked *